Trials / Unknown
UnknownNCT02812121
UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure
Umbilical Cord Blood Derived Mesenchymal Stem Cells Infusion for HBV-Related Acute-on-Chronic Liver Failure: A Randomized Controlled Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 261 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is a severe disease with high mortality. Our previous study have demonstrated that peripheral infusion of bone marrow-derived mesenchymal stromal cells (MSCs) weekly for 4 times is safe and improves 24 weeks survival rate of ACLF patients. In this study, we intend to assess the safety and efficacy of umbilical cord blood derived MSCs for HBV-related ACLF patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | umbilical cord blood mesenchymal stem cells |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-06-01
- Completion
- 2018-06-01
- First posted
- 2016-06-24
- Last updated
- 2016-06-24
Source: ClinicalTrials.gov record NCT02812121. Inclusion in this directory is not an endorsement.